The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

NEW YORK – In cell and gene therapies, the genetic machinery is key to producing the proteins missing or dysregulated in a disease, but whether the therapeutic cassette reaches target cells and how ...

The subcutaneous Perjeta-Herceptin formulation, Phesgo, was a top driver of sales growth in the first quarter of 2025.

Etiome will use its Temporal Biodynamics platform to stage serious, progressive chronic diseases and develop targeted therapeutics.

The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

The €500 million deal is Tessellate's first with a pharmaceutical company and focuses on advancing synthetic lethality therapies ...

Joenja will be the first drug specifically for APDS to be reimbursed within the NHS and is available immediately in England and soon will be in Wales.

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.